

# Nowa opcja w leczeniu osteoporozy

Ranelinian strontu jest obecnie dostępny w Polsce. Preparat legitymuje się wieloletnimi badaniami klinicznymi.

Więcej w portalu <http://www.osteoporoza.pl/index.php?m=news&id=704>

Piśmiennictwo zagraniczne:

1. Ghada El-Hajj Fuleihan, M.D., M.P.H.: Strontium Ranelate – A Novel Therapy for Osteoporosis or a Permutation of the Same? NEJM 2004,5, 504-506.
2. Delmas P.D.: Treatment of postmenopausal osteoporosis. Lancet 2002, 359: 2018-26.
3. De Groen P.C., Lubbe D.F., Hirsch L.J.: et al: Esophagitis associated with the use of alendronate. N.Engl.J.Med. 1996, 335, 1016-1021.
4. Marie P.J., Ammann P, Boivin G., Rey C.: Mechanisms of action and therapeutic potential of strontium in bone. Calcif. Tissue Int., 2001; 69, 121-129.
5. Boivin G., Deloffre P., Perrat B., et al: Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administration. J. Bone Miner. Res. 1996;9, 1302-1311.
6. Boivin G., Deloffre P., Perrat B., et al: Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administration. J. Bone Miner. Res. 1996;9, 1302-1311.
7. Marie PJ, Hott M, Modrowski D, et al. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res 1993 ;8 :607-615.
8. Grynepas MD, Marie PJ. Effects of low doses of strontium on bone quality and quantity in rats. Bone 1990 ;11 :313-319.
9. Meunier PJ, Slosman DO, Delmas PD, et al. Strontium ranelate: dose-dependent effects in established

postmenopausal vertebral osteoporosis: a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002;87:2060-2066.

10. Meunier P.J., Register J.Y.: Design and methodology of the phase 3 trials for the clinical development of strontium ranelate in the treatment of women with postmenopausal osteoporosis. Osteoporos Int. 2003;14 (suppl 3), 66-76.

11. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68.

12. Adami S. ,Meunier P.J., Devogelaer J.P., Hozowski K. et al.: Strontium ranelate reduces the risk of vertebral and non-vertebral fractures in Caucasian women with postmenopausal osteoporosis. Osteoporosis Int. 2004, 15, (suppl. 1) s. 93.

Artykuł poglądowy na temat ranelinianu strontu ukazał się w ostatnim numerze „Terapii” nr 2 z.2/2005.